Log in or Sign up
to access My Account functionalities
HCP Letter for Zeposia (ozanimod) additional risk minimisation material update (2023)
The additional risk minimisation materials for ozanimod were developed as a condition of the marketing authorisation for this product. These materials contain important safety information. Please refer to the attached letter for further information (including information on the recent updates made to one of the materials - the Prescriber's Checklist).